NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial expected in early December 2023Patients who completed the 18-month PARADIGM trial, including the...
United Kingdom Prnewswire Neurosense Therapeutics Ltd Company Phase Drug Administration Exchange Commission European Medicines Agency Neurosense Opens Eu Office
Source: marketscreener.com